SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001493152-22-017446
Filing Date
2022-06-22
Accepted
2022-06-22 09:03:29
Documents
19

Document Format Files

Seq Description Document Type Size
1 formdefa14a.htm DEFA14A 49070
2 formdefa14a_001.jpg GRAPHIC 77145
3 formdefa14a_002.jpg GRAPHIC 334987
4 formdefa14a_003.jpg GRAPHIC 129515
5 formdefa14a_004.jpg GRAPHIC 64135
6 formdefa14a_005.jpg GRAPHIC 272111
7 formdefa14a_006.jpg GRAPHIC 59202
8 formdefa14a_007.jpg GRAPHIC 70189
9 formdefa14a_008.jpg GRAPHIC 73576
10 formdefa14a_009.jpg GRAPHIC 277390
11 formdefa14a_010.jpg GRAPHIC 241477
12 formdefa14a_011.jpg GRAPHIC 258758
13 formdefa14a_012.jpg GRAPHIC 270098
14 formdefa14a_013.jpg GRAPHIC 330762
15 formdefa14a_014.jpg GRAPHIC 336055
16 formdefa14a_015.jpg GRAPHIC 327923
17 formdefa14a_016.jpg GRAPHIC 269372
18 formdefa14a_017.jpg GRAPHIC 60187
19 formdefa14a_018.jpg GRAPHIC 75764
  Complete submission text file 0001493152-22-017446.txt   4910158
Mailing Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932
Business Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932 865-769-4011
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

IRS No.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36457 | Film No.: 221030093
SIC: 2834 Pharmaceutical Preparations